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A B S T R A C T
Objective: Ovarian hyper-stimulation during IVF is associated with a significant raise in serum estrogens
and one may expect detrimental effects on estrogen-dependent diseases such as endometriosis.
However, available evidence from large case series of affected women performing IVF is generally
reassuring with the possible exception of women carrying deep invasive lesions. On this basis we deemed
important investigating more in depth whether women with deep invasive endometriosis could be a
subgroup at higher risk of recurrence or disease progression during IVF.
Study design: Women with endometriosis who underwent IVF and who had a second evaluation after 3–6
months from a failed cycle were retrospectively reviewed. The main inclusion criteria were the presence
of deep invasive endometriosis and/or a history of surgery for this form of the disease. The primary aim of
the study was to determine the frequency of endometriosis-related complications in the interval
between the two evaluations. Secondary aims were pain symptoms and lesion size modifications.
Results: Eighty-four women were ultimately selected: baseline ultrasound documented deep invasive
lesions in 60 of them. One case of possible endometriosis-related complication was recorded,
corresponding to a rate of 1.2% (95%: 0.05%–5.5%) for the whole cohort and 1.7% (95%CI: 0.08–7.6%) for the
subgroup of women with ultrasound detected lesions. This rate appears similar to the reported frequency
of endometriosis progression in women not receiving IVF. No significant modifications in pain symptoms
or lesions size occurred.
Conclusions: Women with deep invasive endometriosis who underwent IVF do not seem to be exposed to
a substantially increased risk of recurrence/disease progression. Larger evidence from independent
groups is however required for a definitive conclusion.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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In vitro fertilization (IVF) is a possible option for the treatment
of infertile women with endometriosis [1,2]. However, IVF not only
exposes women to the well-known general risks of the procedure
but, also, to some specific endometriosis-related risks [3]. Of
relevance here is the hazard of disease-progression during the
procedure. Indeed, endometriosis is an estrogen-dependent
disease and peripheral levels of estrogens increase up to 10-folds
during ovarian hyper-stimulation. Given this premise, some
harmful effects on the natural history of the disease could be
expected. However, the available evidence does not generally* Corresponding author at: Foundation IRCCS Ca’ Granda, Ospedale Maggiore
Policlinico, Infertility Unit and Gynecology Unit, Via Commenda 12, 20122, Milan,
Italy.
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2590-1613/© 2019 Published by Elsevier B.V. This is an open access article under the Csupport this concern [4]. Several independent large case series
failed to highlight major detrimental effects [5–10]. On the other
hand, these reassuring data contrast with some case reports of
severe complications [11–15]. The main characteristics of these
cases are summarized in Table 1. Noteworthy, deep invasive
peritoneal lesions (ie nodules infiltrating the peritoneum by >5
mm) [16] were highly common in these published cases, being
present in at least 9 out of 13 affected women.
On these bases, we hypothesized that women with deep
invasive endometriosis may be a subgroup of women who are
more vulnerable to the potential detrimental effects of ovarian
hyper-stimulation. To the best of our knowledge, only one study
specifically reported evidence on deep lesions and failed to show
detrimental effects. However, the evaluation of the lesions was a
secondary finding, the number of included cases was extremely
limited (n = 9) and the study did not focus on clinical complications
[8]. Given the clinical relevance of the described cases, we deemed
important exploring more in-depth this issue. To this aim, weC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Case reports on the progression of endometriosis during IVF.
Authors, year (N. of cases) Time from IVF to symptoms Description ASRM stage DIE
Renier et al., 1995 (n = 1) 26 days Left hydronephrosis and complete ureteral stenosis n.r. Yes
Govaerts et al., 1998 (n = 2) 2 months Catamenial rectorrhagia Yes
2 months Catamenial rectorrhagia Yes
Anaf et al., 2000 (n = 4) 3 cycles Rectorrhagia, severe digestive symptoms, subocclusion IV Yes
3 cycles Rectorrhagia, severe digestive symptoms, subocclusion IV Yes
1 cycle Rectorrhagia, severe digestive symptoms, subocclusion IV Yes
7 cycles Rectorrhagia, severe digestive symptoms, subocclusion IV Yes
Jun and Lathi, 2007 (n = 5) During stimulation Inreasing pelvic pain II nr
During stimulation Inreasing pelvic pain IV Yes
During stimulation Inreasing pelvic pain II nr
During stimulation Inreasing pelvic pain nr nr
During stimulation Inreasing pelvic pain I nr
Halvorson et al., 2012 (n = 1) 3 days Hydropneumothorax nr Yes
DIE: Deep invasive endometriosis.
nr: not reported.
Studies including pregnant cases were excluded.
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or history of surgery for deep endometriosis who underwent IVF,
and assessed the possible detrimental effects of ovarian hyper-
stimulation for IVF on this selected population.
Materials and methods
All women who underwent IVF cycles between January 2011
and March 2013 at the Infertility Unit of the Fondazione Ca’ Granda,
Ospedale Maggiore Policlinico, Milano were retrospectively
reviewed. Inclusion criteria were: the presence of one or more
deep endometriotic nodules, i.e. nodules infiltrating the peritone-
um by >5 mm [16], and/or a history of surgical removal of deep
invasive endometriosis; the availability of a follow-up evaluation
3–6 months after ovarian hyperstimulation; age <=42 years; failed
cycle (no pregnancy). Women could be enrolled only for one cycle.
The first evaluation was systematically performed at the time of of
the basal clinical and sonographic evaluation that preceded the
initiation of the IVF cycle. The second evaluation was performed
before initiating the second cycle, except in drop-outs from IVF. In
those cases, the evaluation was performed at our referral center for
the general management of endometriosis. Data were thus
extracted by reviewing clinical charts of the whole hospital,
including the Infertility Unit, the Gynecological Unit, the outpa-
tient center for endometriosis management and the obstetrical
and gynecologic emergency department. The local institutional
review board approved the study. A specific informed consent was
not obtained because the study is retrospective. However, women
referring to our units are routinely requested to provide an
informed consent for their clinical data to be used for research
purposes and those denying this consensus were excluded.
At our institution, women with endometriosis are systemati-
cally interviewed at every clinical evaluation about dysmenorrhea,
inter-menstrual pelvic pain and dyspareunia using both a 11-point
verbal rating scale (VRS) and the Biberoglu and Behrman (BB) scale
[17]. The VRS grades pain from 0, indicating the absence of pain, to
10, indicating the worst possible pain. The BB scale defines
dysmenorrhea according to loss of work efficiency and need for
bed rest, non-menstrual pain according to various degrees of
discomfort and use of analgesics, and deep dyspareunia according
to limitation of sexual activity. The presence of other endometri-
osis-related symptoms, including dyschezia, proctorragia, unex-
plained vaginal bleeding and dysuria was also actively
investigated. Women assuming hormonal therapy (oral contra-
ceptives, progestins, GnRH analogues) before entering the IVF
program were requested to discontinue the therapy during the IVF
cycle but also to resume it immediately after the cycle in case offailure. Moreover, women were interviewed about possible urgent
events that occurred since the last visit, thus consenting to collect
data on possible IVF-related complications and endometriosis
recurrence/progression. The latter was defined as the need to
undergo surgery or to start/change hormonal treatment. Finally,
based on the policy of our hospital, a follow-up through phone
contacts was systematically performed in women who did not
attend the scheduled appointments and reasons for non-referral
were recorded. Women reporting that they did not refer because of
endometriosis or IVF-related complications could be included for
the primary outcome.
Transvaginal ultrasound (US) was performed at every clinical
evaluation. Seven sonographers with many years of experience in
reproductive medicine performed all the evaluations. Deep
nodules were defined as hypoechoic lesions with irregular outer
margins and few blood vessels within and around the nodules at
Doppler examination [18]. We included nodules that could be
visualized at US in proximity with the uterine cervix, or behind the
cervix (posterior compartment) or within the bladder wall
(anterior compartment). No attempt was made to identify lesions
located in other more distant sites. The dimensions of the nodules
were measured in three orthogonal planes.
During the IVF cycle, women were monitored and managed
according to a standardized clinical protocol as reported elsewhere
[8]. Briefly, the regimen and the dose of gonadotropins were was
determined on an individual basis according to age, day 3 serum
FSH, serum anti-mullerian hormone (AMH) and Antral Follicle
Count (AFC). During the stimulation, women underwent serial
transvaginal US and serum hormonal assessments when indicated.
When leading follicles with a mean diameter >18 mm were
visualized, human chorionic gonadotropin (hCG) was adminis-
tered subcutaneously. Cycles could be cancelled because of low or
hyper-response. Oocyte retrieval was performed transvaginally 36
h after the hCG injection. Embryo transfer was performed 48–72 h
after the oocyte collection or, in properly selected subjects, at
blastocyst stage.
The primary aim of the study was to determine the frequency of
endometriosis-related complications in women with deep invasive
lesions who underwent ovarian hyperstimulation for IVF. Recur-
rent or progressive cases were considered as complications. They
were generally defined the need to undergo surgery or to start or
change hormonal treatment. A stringent definition of complication
was not stated a priori given the wide and complex spectrum of the
possible clinical conditions reported in the literature (Table 1).
Secondary endpoints included the modification of pain symptoms
and nodule dimensions. The planned sample size (at least 70
women) was based on the assumption that the risk of progression
Table 3
Characteristics of the IVF cycles in the studied population (n=84).
Characteristics Mean  SD, Median (IQR)
or Number (%)
Stimulation protocol
Long protocol 24 (29%)
GnRH antagonist 33 (39%)
Flare up 27 (32%)
Cancelled cycle
Poor response 6 (4%)
Hyper response 3 (7%)
Total dose of FSH used (IU) 3,357  1,621
Duration of hyper-stimulation (days)a 11  3
Number of oocytes retrieveda 5,5 (2–9)
Number of suitable oocytes 3 (1–6)
Fertilization techniqueb
IVF 28 (47%)
ICSI 33 (53%)
Number of cleavage stage embryosc 3 (1–4)
Number of top quality embryosc 1 (0–2)
SD: Standard Deviation. IQR: Interquartile Range.
a Data referring to patients who underwent oocytes collection (n = 75).
b Data referring to patients who retrieved oocytes (n = 61).
c Data referring to patients who obtained embryos (n = 56).
Table 4
Modification of pain symptoms in studied population (N = 84).
Symptoms Before IVF After IVF p
Dysmenorrhea
BB scale 0.3
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This rate was arbitrarily postulated based on an expected 10%
annual risk of recurrence [19] (that actually corresponds to 2.5–5%
at 3–6 months) that was halved considering that a consistent
proportion of women (about half in our population) was assuming
hormonal therapies, a treatment that is known to markedly reduce
the risk of recurrences [20]. The sample size was calculated setting
type I and II errors at 0.05 and 0.20, and considering as clinically
important a fourfold increase in the recurrence/progression rate
compared with expected event rate (>8% instead of 2%). Statistical
analyses were performed using the Statistical Package for Social
Sciences 23.0 (SPSS Inc., Chicago, IL, USA). Probability values below
0.05 were considered statistically significant. The 95% confidence
interval (95%CI) of proportions was calculated using a binomial
distribution model. Modifications of symptoms and dimension of
lesions over time (within-patient comparisons) were tested using
the paired non-parametric Wilcoxon test or the McNemar test, as
appropriate.
Results
Eighty-four women were selected. Baseline characteristics of
thesewomen are shown inTable 2. Fifty womenwhowere diagnosed
with deep invasive endometriosis at baseline evaluation did not
undergo previous surgery for this disease form. The remaining 34
participants underwent previous surgical excision of deep invasive
lesions, and in ten of them surgery was reported to be incomplete.
Lesions could actually be documented in all these latter cases,
whereas no lesions could be detected in the 24 women who received
complete surgery. Overall, 60 women (71%) entered IVF carrying US
detectable deep invasive lesions, and another 24 (29%) had a history
of surgery for deep nodules, but a negative baseline US for these
lesions before starting ovarian hyperstimulation. Endometriotic
nodules were identified in the posterior and anterior compartments
in 58 and 2 women, respectively. IVF outcome for the whole cohort is
shown in Table 3. The distribution of the type of protocols of
hyperstimulation reflects our routine practice as described in
previous studies [7,8]. The median time between the IVF cycle
and the second evaluation was 4 (range 3–6) months.
One woman was admitted to the hospital after the IVF cycle.
This patient carried a rectovaginal non-operated nodule of 15 mm.
She had previously undergone surgery for the removal of a right
inguinal endometriotic lesion. Pre-IVF urinary tract US, barium
enema and colonscopy were unremarkable. She was treated with a
flare-up protocol and hMG 300 IU daily for 10 day. Six oocytes were
retrieved, of whom 5 were in metaphase II. The day after oocytes
retrieval, the patient was admitted to the gynecological division
because of severe pelvic and left lumbar pain. Transvaginal US was
unremarkable (apart from the expected enlarged ovaries and theTable 2
Baseline characteristics of studied population (n=84).
Characteristics Mean  SD, Median (IQR)
or Number (%)
Age (years) 33.6  3.6
Smoking 15 (18%)
Duration of infertility (years) 2 (1–3)
Previous pregnancies 14 (17%)
Previous surgery for endometriosis 41 (48%)
Previous surgery for deep endometriosis 34 (40%)
Patients on hormonal therapy 42 (50%)
BMI (Kg/m2) 21.3  2.2
Day 3 serum FSH (IU/mL) 9.3  5.1
AMH (ng/ml) 1,58 (0,64–2,92)
CA-125 (IU/mL) 39,2 (26–65,4)
Concomitant male factor 29 (35%)unchanged rectovaginal nodule) but computer tomography
showed a narrowed left ureter, that was adherent to a 7 cm left
ovary with multiple copora lutea, and a mild ectasia of the renal
pelvis of 1 cm. An expectant management with close monitoring of
the renal function and the renal pelvic ectasia was decided. Both
symptoms and radiologic signs regressed in two weeks. No other
episodes occurred in the following months. The woman returned
for the transfer of her embryos (that were frozen because of the
pain symptoms), did not achieve pregnancy and then refused to
undergo new hyper-stimulation cycles. No other women under-
went surgery or had to initiate/modify hormonal treatments. No
patient developed de-novo endometriotic lesions after the IVF
cycle. On these bases, we extrapolated a rate of complication of
1.2% (95%: 0.05%–5.5%) (1 out of 84) for the whole cohort and 1.7%
(95%CI: 0.08–7.6%) (1 out of 60) for the subgroup of women with US
detectable lesions.
Table 4 shows the modifications of deep endometriosis related
pain symptoms before and after IVF. More than half of recruited
women presented endometriosis-related symptoms either before0 32 (38%) 26 (31%)
1 12 (14%) 13 (15%)
2–3 40 (48%) 45 (54%)
VRS scale 5 (0–8) 6 (0–8) 0.3
Dyspareunia
BB scale
0 28 (33%) 32 (38%) 0.4
1 25 (30%) 23 (27%)
2–3 31 (37%) 29 (35%)
VRS scale 1 (0–6) 2 (0–6) 0.1
Intermenstrual pelvic pain
BB scale 0.3
0 33 (39%) 29 (35%)
1 22 (26%) 22 (26%)
2–3 29 (35%) 33 (39%)
VRS scale 3 (0–5) 2 (0–6) 0.4
BB: Biberoglu-Behrman Scale. VRS: Verbal Rating Scale.
VRS is reported as median (interquartile range).
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stimulation as compared to baseline. Finally, in the 35 patients who
underwent serial sonographic evaluations, the mean diameter of
the endometriotic nodules was 19  6 mm before IVF and
18  7 mm after IVF (p = 0.60).
Comment
In our experience IVF was a safe procedure for women with
deep invasive endometriosis. Only one woman was admitted to the
hospital for a condition of hydronephrosis presumably related to
deep invasive endometriosis, corresponding to a rate of 1.2%
(considering the whole cohort) or 1.7% (considering exclusively
women carrying US detectable lesions). This rate is in line with the
expected 2% rate of endometriosis progression of over a 3–6-
month period in women not receiving IVF and significantly below
the threshold of 8% stated as clinically important in our sample size
justification (the upper limits of the 95% CIs were <8% for both
calculations). The safety of the procedure is also supported by our
secondary analyses, i.e. the absence of relevant effects on
symptoms and lesions dimension.
The observed case of endometriosis progression deserves some
additional comments. Given the regression of the symptoms with
expectant management, the interpretation of this case remains
unclear. A ureteral stricture caused by the enlargement of an
undetected deep endometriotic nodule underthe stimulation effects
of enhanced peripheral estrogens seems unlikely. Indeed, even if it is
plausible that a deep nodule of the broad ligament could be missed at
baseline evaluation (this diagnosis can be challenging), it is
noteworthy that both the US and the computer tomography done
at the time of the complication did not detect ureteral nodules.
Moreover, symptoms regressed over a couple of weeks concomi-
tantly to the progressive decrease in the size of the ipsilateral ovary.
This observation argues against a rapid growth of a nodule, a
condition that is likely to be irreversible. In our opinion, the most
plausible explanation is a transient kinking of the ureter course
consequent to the local traction of the enlarged and adherent ovary
that was firmly adherent to the broad ligament. The growth of the
ovary could have caused some tractions on a fibrotic area involving
the ovary, the broad ligament and the ureter, actually pulling the
ureter and causing a temporary narrowing of the lumen.
Overall, our results are in line with those emerging from large
case series of women with endometriosis in general. Indeed,
several independent authors failed to highlight detrimental effects
in affected women undergoing IVF [5–10]. Our results actually
extend this reassuring conclusion to the population of women with
a diagnosis of deep invasive endometriosis. On the other hand,
caution in the interpretation of our findings is warranted in light of
the inconsistency with the previously published case reports
(Table 1). A publication bias is plausible for these cases but we
cannot exclude that progression may occur in a minority of women
with some peculiar clinical characteristics. Our findings have two
clinical implications. Firstly, physicians engaged in ART should
inform women with deep invasive endometriosis that the disease
may worsen during ovarian hyper-stimulation but can also be
reassuring on this regard, explaining in particular that this event is
rare. Secondly, our findings argue against prophylactic surgery in
women with deep invasive endometriosis scheduled for IVF. Based
on our findings, systematically removing these lesions exclusively
based on a hypothetical risk of progression seems unjustified.
Exposing women to the risks and costs of a demanding surgery
only for the purpose of preventing IVF-related deep endometriosis
progression and complications seems unwise. Surgery may be
considered before IVF, but the decision should be based on a
comprehensive evaluation that does not consider the potential
prevention of disease progression as the main indication [3].Some limitations of our study should be acknowledged. Firstly,
the study is retrospective and the quality of the information is
inevitably sub-optimal. For instance, while data on pain symptoms
was systematically and prospectively ascertained in our hospital, a
precise measurement of deep lesions on three orthogonal planes
was not (this information was available in the two assessments in
only 35 women). Moreover, drop-outs could be negatively biased
(i.e. women experiencing worsening of symptoms could be more
likely to give up). On the other hand, it has to be underlined that we
were mainly interested in demanding clinical complications. This
latter outcome was actually not exposed to a significant risk of
under-reporting because data was actively obtained for the whole
hospital, including the Infertility Unit, the Gynecological Unit and
the Emergency department. Moreover, women who did not return
to the scheduled appointments were systematically called by
phone to investigate the reasons, thus allowing to rule out severe
complications. Secondly, one could question the decision to
include also women with a history of surgery for deep invasive
endometriosis but without US detectable lesions. This choice was
based on the idea that deep invasive endometriosis is a multifocal
recurrent disease and that the diagnosis of deep lesions may be in
some cases challenging [21]. Some lesions could actually be
overlooked during surgery or could have recurred but not
identified postoperatively. In this regard, it has to be underlined
that, the results were substantially similar when we repeated the
analyses including only women with ultrasound detectable
lesions. Thirdly, even if our sample size allowed us to draw a
conclusion for the whole group of women with deep invasive
endometriosis, subgroup analyses based on the characteristics of
the lesions could not be performed. Further evidence taking into
consideration the dimension, the multifocality and the precise
location of the lesions is needed. To note, one cannot exclude that
the demanding cases reported in Table 1 could have occurred in
women with most severe forms of the disease. Unfortunately, our
study cannot rule out this possibility. Indeed, most women in our
cohort were poorly symptomatic. For instance, clinically relevant
dyspareunia, a typical symptom of deep peritoneal endometriosis,
was present in only one third of our patients (Table 4). Fourthly, a
follow-up period of 3–6 months could be considered too short to
identify every possible complication. However, such a short period
has been chosen in order to focus our attention only to events that
could be strictly related to IVF and ovarian hyper-stimulation,
minimizing the possible influence of other confounding factors. To
note, all the cases of progression of deep endometriosis after IVF
described in literature occurred within three months after ovarian
hyperstimulation (Table 1). Finally, we inevitably lack a definite
histological diagnosis of endometriosis. However, this limitation is
unlikely to play a relevant confounding effect since the accuracy of
transvaginal sonographic diagnosis of deep invasive endometriosis
is high, at least for distal localizations [22,23].
In conclusion, our study suggests that women with deep
invasive endometriosis who undergo IVF are not exposed to a
substantial increase in the risk of recurrence or disease progres-
sion. However, given that demanding complications may occur in
some particular patients, further large studies are required for a
definitive conclusion.
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